DEA approves UC center for medicinal cannabis studies

November 30, 2001

November 28, 2001 - The University of California's Center for Medicinal Cannabis Research (CMCR), has received Drug Enforcement Administration (DEA) approval to begin two clinical studies on the possible efficacy of cannabis in the treatment of two severe medical disorders.

The studies approved by the DEA are:

DEA Administrator Asa Hutchinson said "this announcement is consistent with the DEA position that the question of whether marijuana has any legitimate medical purpose should be determined by sound science and medicine".

Igor Grant, M.D., director of the CMCR at the University of California, San Diego (UCSD) stated that "the approval of these clinical trials by the DEA and other federal and state agencies provides a unique opportunity to conduct much needed rigorous scientific studies that can determine if cannabis products have a role in ameliorating suffering or improving prognosis in severe medical conditions for patients that might not have benefited fully from other treatments."

In addition to exploring possible benefits, these studies will monitor potential side effects and toxicities. In particular, the following sub-study will investigate effects on complex behaviors such as driving skills.A further study at University of California, San Francisco (UCSF) is pending DEA approval, anticipated in the near future. The CMCR, headquartered at UCSD and UCSF, is a statewide, state-funded initiative to study the safety and efficacy of medicinal cannabis to treat certain medical conditions. The Center supports and coordinates scientific research at universities and research centers throughout California, assessing the use of cannabis as an alternative for treating specific medical conditions. Diseases and conditions targeted for treatment are those that have been identified as warranting further research by the National Academy of Sciences, Institute of Medicine, and by a National Institutes of Health expert panel.

Before studies are submitted to the state and federal regulatory review agencies, an external Scientific Review Board, composed of national senior scientists, conducts a thorough review of each study, only approving studies of the highest scientific standards. The CMCR also has a National Advisory Council in place to advise and assist the Center's directorate.

After approval by the Scientific Review Board, each of the above studies were approved by the Research Advisory Panel of California, the Department of Health and Human Services (DHHS), the National Institute on Drug Abuse (NIDA), the Food and Drug Administration (FDA), and the Drug Enforcement Administration (DEA). The studies will order product from NIDA and are expected to begin recruitment at the beginning of next year.
-end-


University of California - San Diego

Related Multiple Sclerosis Articles from Brightsurf:

New therapy improves treatment for multiple sclerosis
A new therapy that binds a cytokine to a blood protein shows potential in treating multiple sclerosis, and may even prevent it.

'Reelin' in a new treatment for multiple sclerosis
In an animal model of multiple sclerosis (MS), decreasing the amount of a protein made in the liver significantly protected against development of the disease's characteristic symptoms and promoted recovery in symptomatic animals, UTSW scientists report.

Not all multiple sclerosis-like diseases are alike
Scientists say some myelin-damaging disorders have a distinctive pathology that groups them into a unique disease entity.

New therapeutic options for multiple sclerosis in sight
Strategies for treating multiple sclerosis have so far focused primarily on T and B cells.

Diet has an impact on the multiple sclerosis disease course
The short-chain fatty acid propionic acid influences the intestine-mediated immune regulation in people with multiple sclerosis (MS).

The gut may be involved in the development of multiple sclerosis
It is incompletely understood which factors in patients with multiple sclerosis act as a trigger for the immune system to attack the brain and spinal cord.

Slowing the progression of multiple sclerosis
Over 77,000 Canadians are living with multiple sclerosis, a disease whose causes still remain unknown.

7T MRI offers new insights into multiple sclerosis
Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI -- a far more powerful imaging technology -- to further examine LME in MS patients

How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.

Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.

Read More: Multiple Sclerosis News and Multiple Sclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.